<?xml version="1.0" encoding="UTF-8"?>
<p>Prophylactic administration of myeloid growth factors has become standard treatment to reduce the incidence of chemotherapy‐induced severe neutropenia, particularly recommended for therapies associated with a ≥20% risk of febrile neutropenia due to both chemotherapy regimen and individual patient risk factors 
 <xref rid="cam41388-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="cam41388-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="cam41388-bib-0020" ref-type="ref">20</xref>. Rolontis is being developed as a novel long‐acting form of G‐CSF that has a distinct structure compared to pegfilgrastim and may represent a more potent new G‐CSF that delivers improved clinical efficacy.
</p>
